- Home
- GLRE vs CYRX Comparison
GLRE vs CYRX Comparison
Compare GLRE & CYRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GLRE | CYRX |
|---|---|---|
| Founded | 2004 | 1999 |
| Country | Cayman Islands | United States |
| Employees | N/A | 1100 |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.5M | 419.3M |
| IPO Year | 2007 | 2008 |
Fundamental Metrics
Financial Performance| Metric | GLRE | CYRX |
|---|---|---|
| Price | $16.76 | $7.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $12.94 |
| AVG Volume (30 Days) | 177.0K | ★ 425.4K |
| Earning Date | 03-09-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 75.00 | ★ 156.22 |
| EPS | ★ 2.17 | 1.40 |
| Revenue | ★ $729,777,000.00 | $176,177,000.00 |
| Revenue This Year | N/A | $10.92 |
| Revenue Next Year | N/A | $8.08 |
| P/E Ratio | $7.89 | ★ $5.86 |
| Revenue Growth | ★ 4.85 | N/A |
| 52 Week Low | $11.57 | $4.63 |
| 52 Week High | $17.47 | $11.45 |
Technical Indicators
Market Signals| Indicator | GLRE | CYRX |
|---|---|---|
| Relative Strength Index (RSI) | 66.50 | 40.89 |
| Support Level | $12.66 | $6.57 |
| Resistance Level | $17.02 | $7.88 |
| Average True Range (ATR) | 0.56 | 0.40 |
| MACD | 0.10 | 0.04 |
| Stochastic Oscillator | 74.83 | 18.27 |
Price Performance
Historical ComparisonAbout GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About CYRX CryoPort Inc.
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.